JWH-363

From WikiMD's Wellness Encyclopedia

JWH-363 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent and selective CB2 receptor agonist, with a Ki of 23.2 nM at CB2 and 152 nM at the CB1. This makes it almost 7x more selective for the CB2 subtype. The compound was invented by John W. Huffman, an organic chemist who designed a range of these compounds for use in scientific research.

Chemistry[edit | edit source]

JWH-363 is part of the JWH series of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids including JWH-018, JWH-073, and JWH-200. The compound is a naphthoylindole, meaning it has a core indole structure with a naphthoyl group attached. The specific structure of JWH-363 includes a methoxy group at the 4-position of the naphthoyl ring.

Pharmacology[edit | edit source]

JWH-363 acts as a potent and selective agonist for the CB2 receptor, with a Ki of 23.2 nM. This makes it almost 7x more selective for the CB2 subtype over the CB1 receptor, which it binds with a Ki of 152 nM. The CB2 receptor is primarily found in the immune system, while the CB1 receptor is mainly located in the brain. This selectivity may result in different effects compared to non-selective cannabinoids.

Legal Status[edit | edit source]

As of October 2015, JWH-363 is a controlled substance in China. Its legal status in other countries may vary, and it may be controlled under analogue laws in countries such as the United States.

See Also[edit | edit source]

JWH-363 Resources




Contributors: Prab R. Tumpati, MD